Aquestive Therapeutics (AQST) Net Margin (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Net Margin of 55.77% for Q1 2026, up 20719.0% year-over-year from N/an in Q1 2025, and down 153.55% quarter-over-quarter from 104.14% in Q4 2025.
Aquestive Therapeutics (AQST) Net Margin (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Net Margin history runs 10 years deep, the most recent figure standing at 55.77% for Q1 2026.
- In Q1 2026, Net Margin rose 20719.0% year-over-year to 55.77%; the TTM figure through Mar 2026 stood at 1034.08% (down 93406.0% YoY), while the FY2025 annual figure was 8932.2%, down 885552.0% from the prior year.
- Net Margin for Q1 2026 stood at 55.77%, down from 104.14% in the prior quarter.
- The five-year high for Net Margin was 104.14% in Q4 2025, with the low at 262.96% in Q1 2025.
- The 5-year median for Net Margin is 106.43% (2024), against an average of 82.61%.
- The sharpest annual moves came in 2022 and 2024: Net Margin soared 41458 bps in 2022, then plunged 17889 bps in 2024.
- Aquestive Therapeutics' Net Margin stood at 115.63% in 2022, then soared by 47 bps to 61.42% in 2023, then plunged by 134 bps to 143.72% in 2024, then surged by 172 bps to 104.14% in 2025, then tumbled by 154 bps to 55.77% in 2026.
- Business Quant data shows AQST's Net Margin at 55.77% in Q1 2026, 104.14% in Q4 2025, and 120.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -13.91% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 9.28% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 42.51% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -3.16% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 15.06% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 3.95% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Aquestive Therapeutics | 556.36 Mn | 556.36 Mn | 9.80 Mn | -165.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -165.45% |
| Mar 31, 2026 | -55.77% |
| Dec 31, 2025 | 104.14% |
| Sep 30, 2025 | -120.61% |
| Jun 30, 2025 | -135.44% |
| Mar 31, 2025 | -262.96% |
| Dec 31, 2024 | -143.72% |
| Sep 30, 2024 | -84.99% |
| Jun 30, 2024 | -13.66% |
| Mar 31, 2024 | -106.43% |
| Dec 31, 2023 | -61.42% |
| Sep 30, 2023 | -15.65% |
| Jun 30, 2023 | -43.74% |
| Mar 31, 2023 | 72.46% |
| Dec 31, 2022 | -115.63% |
| Sep 30, 2022 | -109.36% |
| Jun 30, 2022 | -203.78% |
| Mar 31, 2022 | -107.74% |
| Dec 31, 2021 | -261.28% |
| Sep 30, 2021 | -109.54% |